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INTRODUCTION 
During the last few years * the interests of the 
surgeon and the immunologist have been focused on the 
remarkable immuno-suppressive powers of antilymphocyte 
serum. Such serum has come into use in experimental and 
clinical organ transplantation in many series. We shall 
here discuss what is currently known about its specificity 
and mode of action. 
The work of several early investigators with anti¬ 
leucocyte sera has been well summarized by Russell and 
Monaco (31). In 1937* Chew and Lawrence (6) demonstrated 
that a serum raised in rabbits against guinea pig lymph 
node cells produced a fall in total lymphocyte counts when 
administered to guinea pigs* and that daily Injections 
could maintain lymphopenia up to ten days. Lymphocyte 
counts were depressed from a level of ^-5*000 to 1*000 or 
less* but Increasing doses could not totally ablate peri¬ 
pheral lymphocytes. They found a generalized hyperplasia 
of lymphoid tissue* which was also seen after injections 
of normal rabbit serum. In 19^1* Cruickshank (7) demonstra¬ 
ted lymphopenia in rats given rabbit anti-rat lymphocyte 
serum* and showed that incubation of such serum with rat 
lymphocytes utilized complement. He also noted lymph node 
hyperplasia. 
In 1956* Interbitzin (12) demonstrated that antilympho¬ 
cyte serum inhibits tuberculin sensitivity in rats. 
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Wilhelm et al., in 1958., (36) noted that administration 
to guinea pigs of rabbit anti-"mononuclear" serum induced 
a depletion of circulating mononuclear cells., which was 
correlated with a marked reduction in allergic contact 
sensitivity* The growing awareness of the role of lympho¬ 
cytes in depayed hypersens itivity, and, specifically, 
allograft rejection, led Woodruff (37) to investigate the 
effects of antilymphocyte serum on allografts of skin and 
endocrine tissue in rats* These experiments were unsuccess¬ 
ful, but Woodruff has recently admitted (40) that the sera 
used were not sufficiently potent and the doses too small. 
In 1961, Waksman et al. (35) reported definite reduction 
in a variety of reactions of the delayed type after treat¬ 
ing guinea pigs with rabbit anti-guinea pig lymphocyte serum. 
A slight, but definite, prolongation of first set allografts 
was notedj there was also some histological evidence of 
slightly delayed rejection of second-set grafts. Repeated 
injections of the antiserum over several days produced 
lymphopenia which became less marked with continued treat¬ 
ment. Clear-cut depletion of small lymphocytes in lymph 
nodes was noted, 
McGregor and Gowans (27, 28) showed that chronic 
depletion of rat small lymphocytes by a thoracic duct 
fistula led to a marked reduction in various Immorally 
mediated immunologic responses, as well as a definite 
prolongation of first set allografts. They were unable to 
affect secondary humoral responses or second set grafts. 
They could not conclude, however, that lymphocytes are not 
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involved, in the latter reactions,in view of a personal 
communication from Mithchell and Gowans that a typical 
secondary response followed the first challenge of rats 
with diphtheria toxoid occurred, if these rats has previ¬ 
ously been given lymphocytes from other, primarily sensi¬ 
tised rats. 
Woodruff and Anderson (38, 39) were the first to 
demonstrate marked prolongation of skin graft survival 
with antilymphocyte serum; they used a rabbit anti-rat 
lymphocyte serum, and showed prolonged survival even when 
distantly related rats were used as donor and recipient. 
They reported that the lymphocyte count tended to rise 
during the course of serum treatment. Sacks et al, (32) 
showed that, in rats given rabbit anti-rat lymphocyte serum, 
the degree of lymphopenia at 2h hours was dose dependent; 
furthermore, the lymphopenic effect persisted on long-term 
treatment. To explain this effect, they suggested, but did 
not document, that their serum was able to suppress anti¬ 
body formation against itself. Hemagglutinins and hemo¬ 
lysins present in the serum could be absorbed without 
interfering with the lymphopenic effect. This has been a 
consistent observation in reports,from other laboratories. 
Sacks et al., in the same article, reported gel- 
diffusion studies that demonstrate precipitin activity of 
their antilymphocyte serum against a variety of rat tissue 
homogenates. Precipitin bands were formed against lymphoid 
tissue, kidney, liver, and (weakly) muscle, A spur was 
seen on the middle lymph node band that went beyond the 
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joining kidney band. Two bands were seen with the lymph 
node homogenate that were not present against other tissues. 
These data were interpreted to suggest that lymphoid tissue 
may contain antigens not present on other tissues, 
Nagaya and Sieker (29) showed that an antiserum to 
thymus cells was more effective, as measured by lympho¬ 
penia and allograft survival, than antiserum to mesenteric 
lymph node cells. The results previously observed in rats 
have been reproduced in mice by Gray et al. (10), Monaco 
et al, (26), and Levey and Medawar (20,21). These groups 
demonstrated prolongation of second-set as well as first- 
set skin grafts. 
James (15) has reviewed many current studies demonstra¬ 
ting usefulness of antilymphocyte antibody in protecting 
renal transplants against rejection, as well as its effect 
on humoral antibody formation and other immune phenomena. 
Whole serum and globulin fractions have been immunosuppres¬ 
sive in just about all systems studied, except, notably, 
formation of secondary humoral antibody (e.g. Monaco et al,, 
26). 
Gray, et al. (10) reported that blood taken from mice 
one week after the last of 9 injections, over two weeks, of 
.25 c.c. of rabbit anti-mouse lymphocyte serum, contained 
little or no activity against rabbit gamma globulin, as 
compared to high titers in mice given equivalent doses of 
normal rabbit serum. The control was thought to rule out 
immunological paralysis as a mechanism, and the authors 
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by their serum* of antibody formation against itself. Lance 
and Dresser (19), however* showed* in a very elegant experi¬ 
ment studying disappearance rates of isotopically labelled 
globulins* that antilymphocyte serum could be immunogenic 
in doses producing potent immunosuppression. In fact* 
it seemed to be more immunogenic than normal serum. Their 
data were interpreted to suggest that unresponsiveness in 
mice to rabbit serum* after prolonged periods of exposure 
to rabbit anti-mouse lymphocyte serum* may actually repre¬ 
sent immunological paralysis. The key point* in order for 
antilymphocyte serum to maintain unresponsiveness against 
itself would seem to us to be the use of it in high doses 
continually; this conclusion is consistent with both 
protocols, Lance and Dresser*s protocol shows immuno¬ 
genic ity of antilymphocyte serum* as measured by rapid 
elimination of a dose of normal rabbit serum administered 
several weeks after the injections of antilymphocyte serum; 
in contrast* Monaco’s observation is that a single, inten¬ 
sive course of a potent serum can fail to produce measure- 
able anti-globulin activity when there is no subsequent 
challenge. Indeed* In a more recent paper* Russell and 
Monaco (31) have shown that a small injection of their 
serum* followed several months later by a second injection, 
will indeed incite formation of anti-globulin. 
Starzl et al. (3*0 have recently shown that human 
renal allograft recipients treated with anti-lymphocyte 
serum in their series developed significant precipitin 
titers against ALS* and that this reaction could be 
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attenuated by simultaneous use of steroids. Their data 
also suggest that a spontaneous decline in late host 
reaction to foreign protein may occur during serum treat¬ 
ment. It is not clear from his data whether this phenomenon 
represents specific ALS-inauced immunosuppression of 
reaction against itself, or a less specific immune paralysis 
James (15) has reviewed other studies which show In 
recipients of antilymphocyte serum, either antibodies 
against donor globulin, rapid "immune" elimination of 
anti-lymphocyte IgG, or "immune complexes" in transplanted 
organs. Monaco’s serum seems to be among the strongest 
of those reported so far, at least as measured by persis¬ 
tence of lymphopenia, and suppression of reaction against 
itself. Perhaps the clinical lesson is that very strong 
sera or fractions must be produced if ALS is to enjoy 
clinical usefulness, and,again, that it must be used in 
high doses without interruption if used at all. 
Much has been written about the specificity and mode 
of action of anti-lymphocyte serum. The obvious assump¬ 
tion from early experiments might be that the serum acts 
specifically on lymphocytes, and t,hat the mechanism is 
cell lysis. Recent reports have called into question both 
of these ideas, however. We shall here attempt to review 
current studies relating to these two questions. It is 
difficult to make a complete distinction between specificity 
and mode of action; some objections pertain to both 
questions. We shall treat the questions separately, however 
even though the discussions will overlap somev.liat. 
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G-ray, et al, (10) feel that their serum acts primarily 
by specific immune lysis of lymphocytes, both central and 
peripheral. Their serum had strong agglutinating and 
cytotoxic activity against, mouse lymph node cells of 
several strains, as well as precipitin activity in gel 
diffusion against mouse lymph nodes, spleen, liver, kidney, 
i 
and muscle: homogenates. As with Sacks’s (32) earlier gel 
diffusion study, serum diffusing against spleen and lymph 
node homogenates produced some lines which were not present 
against other tissues. In addition, these authors showed 
that absorption with mouse liver and kidney removed precipi¬ 
tin lines against these tissues, but left unaltered the 
precipitin line against spleen and lymph nodes. In contrast, 
absorption with spleen or lymph node cells removed 
precipitin lines against all tissues. Cytotoxic, activity 
of their serum against lymph node cells could also be 
markedly reduced by absorption with spleen or lymph node 
cells, but not with liver or kidney cells. The same effects 
were noted (but data not presented) on lymphagglutinin 
titers. Finally, absorption with lymphoid cells could 
remove the lymphopenic effect of a diluted sample of serum, 
whereas absorption with liver cells could not remove this 
effect. The authors concluded that their serum contained 
antibodies directed against antigens specific to lymph node 
cells. Not all their data are conclusive, however, for 
several reasons. First, the absorptions in their lympho¬ 
penia experiment do not seem to have been complete with 









cells, at least as measured by absolute lymphocyte levels 
after treatment; in addition, it seems they only used one 
animal for each serum tested. Second, they did not titrate 
cytotoxic antibody, but rather measured the effects of 
undiluted sera alone. The maximum percent dead cells in 
their cytotoxic experiment was 55$. Our experiments have 
shown that meaningful data with cytotoxicity (at least 
against myeloma cells) require titration with serial 
dilutions, and that the lowest dilutions with antiserum 
characteristically show 98-100$ cytotoxicity against the 
cell the serum was raised with. Thus it seems difficult 
to interpret some of the data of Gray, et al«, with the 
same enthusiasm as the authors do. Nevertheless, the 
profound and persistent lymphopenia they achieved, as well 
as their gel-diffusion and lymphagglutinin results, strongly 
support their conclusions. In a later report, the same 
group, (31) has shown a picture of a frozen section of a 
human kidney, which they exposed to rabbit antihuman lympho¬ 
cyte serum, washed, and covered with fluorescein-labelled 
goat anti-rabbit gamma globulin antibody; selective 
adherence of the ALS to lymphocytes in capillary tufts is 
clearly demonstrated. This adds much weight to their conten¬ 
tion that immunization with lymphocytes can induce cell- 
specific antisera. 
Woodruff and Anderson (40) noted uptake of antilympho¬ 
cyte antibody, using a similar fluorescent technique, by 
in vitro suspensions of thoracic duct lymphocytes. In this 
report, they did not give data on similar tests with 
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non-lymphoid cells, but they gave evidence that their 
rabbit anti-rat ALS had an insignificant cytotoxic titer 
against peritoneal macrophages of the rat, as opposed to a 
high titer against rat lymphocytes. 
Evidence has been presented, however, that antilympho¬ 
cyte serum is not specific in any histological sense. 
Levey and Medawar (20) have shown that sera prepared in 
rabbits against mouse L cells and mouse basal epidermal 
cells exerted a significant prolongation on murine skin 
allograft survival. None of their sera here was prepared 
according to the protocol they used for all their anti- 
thymic serum. A serum prepared with a number of L cells 
5 times the usual number of thymocytes used, with the 
same protocol of rabbit injections and bleeding, prolonged 
the mean survival time (MST) of allografts 3*7 days beyond 
the MST of control allografts, and prolonged none by more 
than 5.4 days, Antithymic serum administered in the same 
way, as reported in a different paper (21), prolonged 
survival of all grafts at least 8.5 days, half the grafts 
by 18 days, and two (of twenty) by 38 and 52 days, respec¬ 
tively. Their two strongest anti-epidermal sera prolonged 
the MST by 12.1 and 6,6 days, and no grafts were prolonged 
by more than 17.^ and 9*^ days, respectively. Fewer cells 
were used in each injection, but the active sera were 
harvested after four and five injections, respectively, 
whereas all their antithymic sera were harvested after 
two injections. Thus it is impossible to quantitate the 
difference among the effects of their sera, although 
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clearly antithymic serum had the most profound effect. It 
is unfortunate that the authors did not describe the effects 
of their anti-epidermal and anti-cell sera on peripheral 
lymphocytes. Nevertheless, the prolongation exerted by 
these sera on allograft survival is significant, and the 
authors’ contention that ALS is not specific in the histo¬ 
logical sense has considerable merit. We shall discuss 
the point below, in reference to our own experiments. 
The antithymus serum of Levey and Medawar (21) had 
little lymphopenia effect at four hours, after a single 
injection, but the lymphocyte counts apparently fell further 
and were recorded at 7 and 1*1 days as roughly 60-70$ of the 
original level. Although Gray et al. (10) reported a 
substantial fall In lymphocyte counts at four hours, the 
percent of original lymphocytes remaining at ten days was 
not significantly different in their study from that 
attained by Levey and Medawar. 
Several investigators have reported that, during treat¬ 
ment of rats with ALS, lymphocyte depression was not always 
maintained during prolonged allograft survival (Woodruff and 
Anderson, 38; Nagaya and Sieker, 30; Anderson, James, and 
Woodruff, lj Sacks, et al., 32), Certainly these observations 
might cast doubt on the specificity of ALS for lymphocytes, 
or, alternatively, they might call into question the cyto¬ 
toxic theory of action of ALS (which is discussed below). 
Indeed, Levey and Medawar have implied (20) that return of 
peripheral lymphocytes towards normal levels may be irrele¬ 
vant or even desirable. Interpretations of these data as 
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disproving specificity of ALS for lymphocytes could be 
overcome if it could be shown that the return of lympho¬ 
cytes towards normal during treatment represents a compen¬ 
satory increase of a sub-population of unsensitized cells, 
or cells that cannot be sensitized (Levey and Medawar’s 
"sterile activation" theory, discussed below). Similar 
confusion about lymphocyte levels exists in canine trans¬ 
plantation experiments; again, Monaco’s group (25) noted 
persisting lymphopenia, using material prepared with 
adjuvant, while Starzl’s group (33) reported inconsistent 
lymphopenia. 
Aside from the issue of the actual specificity of ALS, 
there are several different theories as to its mode of 
action. These theories have been reviewed in detail by 
Levey and Medawar (21, 23), Bussell and Monaco (31), and 
James (15). The most prominent are the cytotoxic, blind¬ 
folding, competitive antigen, and sterile activation 
theories. 
The first and most obvious theory is that ALS acts 
essentially as a lymphocyte depleting, or cytotoxic, agent. 
We have seen that Gray, Monaco, and Russell have strongly 
advocated this theory. We have cited several papers which 
show that with some sera lymphopenia need not be marked or 
sustained during periods of immunosuppression ( a fact which 
is also relevant to the question of specificity), Levey 
and Medawar (21) have maintained that "the lesser immuno¬ 
suppressive action" of the thoracic duct drainage experi¬ 
ments of McGregor and Gowans (27, 28), which produced "a 
■ 




greater lymphocyte depletion [than is observed with ALSj 
argues against the cytotoxic theory, McGregor and Gowans 
observed that thoracic duct drainage significantly prolonged 
survival of first-set grafts in their non-inbred rats, A 
much lesser but significant effect was recorded in "distantly 
related" animals. The authors were unable to prolong 
second-set grafts, when the course of depletion was begun 
immediately after first-set rejection, Levey and Medawar 
(21) got a significant prolongation of second-set graft 
survival in mice with their antithymic serum, but they 
began the experiment 1-4 days after first-set graft rejection, 
when presumably there may have been more of a decline in 
quantity and quality of sensitization, or when "memory 
cells" may have moved from lymph nodes into the more access¬ 
ible circulation. It seems Levey and Medawar’s arguments 
cannot be accepted until experiments are reported in a 
single species with' parallel courses of thoracic duct 
drainage and anti-lymphocyte serum administration. Woodruff 
and Anderson (38, 39) have reported a synergistic effect 
on rat allograft survival of ALS treatment and thoracic 
duct drainage. They did not do parallel studies isolating 
the two techniques, however. Examination of their graphs 
reveals that a seven day course of ALS (prior to grafting) 
had a more profound lymphopenic effect than thoracic duct 
drainage done over five days. 
An impressive series of experiments has recently come 
out of Woodruff’s laboratory on the immunosuppressive 
properties of various fractions of ALS XgG, James (15) has 
. 
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interpreted the failure of the non-cytotoxic f(ab*)p 
antibody fragment to produce immunosuppression (l, 1^, 16) 
as favoring the cytotoxic theory* This conclusion, of 
course, assumes that in vitro cytotoxicity and in vivo 
cell lysis are equivalent phenomena. 
Perhaps selective destruction of a sub-population of 
lymphocytes in a state of readiness to undertake immune 
responses, and with proportional sensitivity to antilympho¬ 
cyte serum, is the mechanism (20, 16), and failure to 
achieve gross depletion of the lymphocyte population need 
not in itself nullify the cytotoxic theory (l4). 
There are several other theories, based on coating of 
lymphoid cells by antilymphocyte serum without lysis. 
These are the blindfolding, the competitive antigen, and 
the sterile activation theories; they tend to overlap 
somewhat, 
Levey and Medawar (22) showed that lymphocytes from 
CBA mice that had previously rejected skin from C57 mice 
could lyse C57 fibroblast monolayers in vitro, and that such 
lysis could be inhibited by prior incubation of the lympho¬ 
cytes with heterologous antilymphocyte serum. "Blindfold¬ 
ing" of lymphocyte combining sites or recognition units 
might then, they proposed, explain the in vivo mechanism 
independent of cytotoxicity. In further work, however, 
(20) this group found that cells from serum treated donors 
failed to restore immunological competence to previously 
irradiated recipients, even though these cells presumably 







lost their antibody coat. Russell and Monaco (31) have 
recently cited unpublished observations by Dr. B. van der Werf 
in their laboratory* showing that lymphoid cells from ALS 
treated animals failed to produce the usual graft versus 
host reaction in newborn recipients* tending to confirm the 
previous experiment in disproving the blindfolding theory. 
Russell and Monaco concluded that the population of cells 
remaining in lymph nodes after serum treatment was definitely 
incompetent - either from some form of selective destruction 
of competent cells* or because of converstion of competent 
cells to an incompetent form. The latter suggestion, of 
course* is a departure from their previous cytotoxic theories. 
Guttman et al. (ll) have recently suggested a variant 
of the blindfolding theory* that the antibody coats the 
graft tissue* which shares antigens with lymphoid tissue* 
thus preventing histocompatibility antigen release, or 
recognition by the lymphocyte of such antigen ( a mechanism 
similar to immunological enhancement). The authors demon¬ 
strated that prior treatment of hybrid rat donors with 
an antithymic serum leads to a definite uptake of globulin 
in donor kidney tissue* and that transplantation of kidneys 
from these animals into parent strain untreated recipients 
led to definite slowing of rejection. Perhaps Levey and 
Medawar’s anti-epidermal serum (20) might work in part 
through this mechanism in prolonging survival of allografts 
of skin. We have seen how Sacks et al., and Gray* et al., 
have shown by gel diffusion that their rabbit anti-rat 
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that there are probably specific lymphocyte antigens not 
shared by other tissues. Iwasaki et al. (13) have main¬ 
tained that multiple absorptions of their anti-dog lympho¬ 
cyte serum with liver and kidney cells absorbed out 90% of 
the agglutinating activity of the serum. They concluded that 
most of the antigens of the lymphocyte in the dog are 
represented in other tissues. They failed to show whether 
there are any lymphocytes in dog kidney and liver parenchyma. 
The only data they show indicate that a single exposure of 
their serum to kidney or liver reduces the leukoagglutinin 
titer from 1:4096 to 1:1024, and this is termed a 75^ 
reduction in titer. They did not test the leukoagglutinin 
titer of normal horse serum, which is presumably negligible, 
nor did they test the titer of immune serum absorbed with 
identical quantities of lymphoid tissue. It is tempting 
to conclude from these data nevertheless, that most of 
the antigens on lymphoid tissue are represented on other 
tissues. However, other data, in the same report, show 
that absorption of their serum with liver and kidney did 
not alter its lymphopenic effect. 
Cerilli, et al. (5) have recently repeated Guttman’s 
experiment on the treatment of the donor of a kidney with 
antilymphocyte serum before transplantation, to test the 
graft-blindfolding hypothesis. Cerilli et al. used dogs 
instead of rats, and prepared their serum in horses. No 
effect on graft survival was noted, in contrast to Guttman's 
findings with inbred rats. The conclusion was that the 
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small, and only noticeable in an inbred animal system. 
Certainly experiments must be done using sera prepared 
against tissues other than lymphoid organs in dogs to 
clarify this point. We have not seen reports, in any 
system, on the effect of absorption by other organs on 
in vivo immunosuppressive action of antilymphocyte serum. 
The "competitive antigen" theory, in many ways similar 
to the blindfolding theory, differs in involving a 
specific and preferential immunological commitment of 
lymphocytes to anti-lymphocyte antibodies acting as anti¬ 
gens (15). This theory is perhaps supported by the work 
we have quoted showing that, under proper conditions, 
antibody to ALS or normal IgG from the species donating 
the serum may be noted in recipients. James (15) discusses 
the point further. 
The theory of "sterile activation" has been proposed 
by Levey and Medawar (20). The theory is based on their 
observations, and those of other, (6,7) that lymphoid 
hyperplasia and the formation of blast cells occurs in 
lymphoid organs with certain sera and protocols, (in 
contrast. Gray, et al. 10, and Waksman et al,, 35, report¬ 
ed depletion in their studies. Although Monaco and Russell's 
group have consistently seen lymph node depletion in all their 
experiments, they have recently reported (31) "large, foamy 
lymphoid cells In the periphery similar to many of those 
left in lymphoid tissue.") Levey proposed that antilympho¬ 
cyte sera may at least in part act through a sterile acti¬ 
vation of lymphoid cell size and growth rates, forestalling 
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all other Immunological commitments. Grasbeck (9) showed 
earlier that rabbit anti-human lymphocyte serum can 
activate in vitro human lymphocytes mitoticaily. Woodruff 
et al. (4l, 42) have recently shown that horse anti-human 
lymphocyte IgG can stimulate the uptake of Isotopically 
labelled nucleosides into lymphocyte nucleic acid. Ling 
et al. (24) have done a similar experiment, and they showed 
that there is not a constant correlation between trans¬ 
forming antibodies and either cytotoxic or agglutinating 
antibodies, 
There are two major obstacles to the immunosuppressive 
relevance of blast transformation and its in vivo equiva¬ 
lent, sterile activation. First stand the observations 
of Woodruff et al. that the same effect is achieved by 
the divalent f(ab1) IgG fraction (4l); this fraction is 
non cytotoxic, and has no effect on immune responses, at 
least in rats (l, 14). Second, complement must be excluded 
from all in vitro systems using whole immune serum or 
intact IgG, to get blast transformation; otherwise, lysis 
occurs (9*24). It is not unreasonable to assume that 
recipient complement has access to sites of action of 
heterologous antilymphocyte serum. It would seem that the 
crucial experiment to determine the immunosuppressive 
significance of in vitro blast transformation would be 
to test whether antibody treatment, without complement, 
can depress immunologic responses of lymphocytes in culture 
To our knowledge, no such experiment has been published; 
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immunosuppression seems to be in doubt. 
Many questions about the specificity and mode of 
action of antilymphocyte serum are obviously unanswered. 
Questions about its method of action are certainly of more 
than academic interest, especially in respect to the 
rationale for selecting appropriate tests for assaying 
potency of serum batches. Cytotoxicity in vitro, lympho¬ 
penia in vivo, lymphagglutination, or in vitro blast 
transformation are all possibilities, but it is not yet 
known which is the best test. 
It would seem that the more pressing practical 
question,however, concerns the specificity of the serum. 
It seems clear from many papers we have considered, that 
there are many antigenic determinants on the lymphocyte 
of all species studied, A key question, as yet not fully 
answered, is whether there are any antigens peculiar to 
the lymphocyte. The gel diffusion studies of Gray et al, 
(10), as well as those of Sacks et al. (32), indicate 
there may indeed be specific groups on lymphocytes, 
Iwasaki*s serum (13) induced lymphopenia after liver and 
kidney absorption, but there are other data in his paper 
in conflict with this observation. Certainly Levey and 
Medawar (20) attained immunosuppression with anti-epider¬ 
mal, and to a far lesser extent, with anti-L cell serum, 
Levey refers (23) to unpublished work of S.V. Joost that 
rabbit anti-mouse fibroblast serum has a similar effect. 
But in all of these observations of Levey and Medawar, 




lesser effect than their own antithymic serum.. 
It would seem consistent with most reported results 
that there may be some lymphoid-specific antigens. At any 
rate, a most important consideration, consistent with most 
available data, is the possibility that circulating 
lymphoid tissue is a highly vulnerable target, much more 
so than any solid tissues, for reasons of either structural 
weakness, high concentration of antigen (either cell or 
species specific), or just general physical availability. 
For any of these reasons, antibodies raised against lympho¬ 
cytes might be expected to act more quickly and/or effec¬ 
tively against lymphocytes than against tissues not 
involved in the immune response, even if non-lymphoid 
tissues should possess potential binding sites. 
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PURPOSE OF THE EXPERIMENT 
While working as a research assistant in the labora¬ 
tory of Drs. Paul S. Russell and Anthony P, Monaco in the 
summer of 1966, the author became intrigued with the possi 
bilities for use of antilymphocyte serum in clinical 
transplantation work. Access at that time to a draft of 
work later published by Levey and Medawar (20) raised 
many doubts about the specificity of such sera for lympho¬ 
cytes. Accordingly, it was thought appropriate to raise 
a serum against a pure cell line, in the mouse, of non- 
lymphocytic and non-graft origin, and then to attempt to 
elicit and characterize any activity of this serum against 
lymphocytes in vitro and in vivo, comparing this activity 
with any effect this serum might have on the allograft 
response. 
We selected murine myeloma cells as an appropriate 
cell line; we received a specimen of the transplantable 
C3H myeloma X5563* and have maintained this tumor in 
subcutaneous form in this laboratory. Histology of this 
tumor reveals a rather well differentiated cell population 
resembling closely the appearance of normal plasma cells. 
MATERIALS AND METHODS 
Animals 




were used to prepare all antisera. Inbred adult female 
mice of the C3H/HeJ strain were used to carry the tumor, 
and as recipients of all sera and skin grafts. Adult 
female Balb/c mice were used as graft donors. All mice 
were obtained from Jackson Laboratories in Bar Harbor, Maine 
and were not bred in this laboratory. 
Preparation of Myeloma Cells for Immunization 
It was found convenient to maintain the turner in 
subcutaneous form. About ten days to two weeks after 
injection of cells into C3H mice under flank skin,, a large, 
firm mass becomes evident. On exposure, these tissue 
masses are usually white and smooth, with moderate vascu¬ 
larization. For purposes of immunization, tumor cells 
were pressed through a wire screen by a garlic press into 
Hank's medium, under sterile conditions, to separate the 
cells. The method of Gordon et al, (8) was employed to 
separate out non-myeloma elements (this method was origin¬ 
ally described for use with ascites forms of X5563 myeloma, 
but was found adequate for solid subcutaneous tumors here). 
Cell suspensions were centrifuged at 600 RPM in a 2A0 head 
for 3 minutes, after which all supernatent, and, when 
necessary, red cell rings, were removed by aspiration. 
When this procedure had been repeated 10 times, a prepara¬ 
tion of 99% myeloma cells was attained. 
Preparation of Anti-Myeloma Serum 
The protocol of Gray et al. (10) was followed. An 






medium, and emulsified with an equal volume of complete 
Freund’s adjuvant. Several rabbits received 0.2 ml of 
the emulsion into each foot-pad, to give a total of 
100xl0u cells per rabbit. Booster injections of cell 
suspensions {100x10^ cells again) in Hank’s medium were 
given to each rabbit through an ear vein on three successive 
days 4 weeks later. The rabbits were bled by cardiac 
puncture 7 days after the last injection, and on one or 
two subsequent days in those who survived the first massive 
bleeding. All blood samples were allowed to clot and 
stand in the cold (4° C) overnight. Some tubes of immune 
and normal serum showed evidence of gross hemolysis after 
clotting. All sera were separated from the clots and 
pooled, diluting out to unnoticeable color any hemoglobin 
contamination. All sera were immediately heated to 56° C 
for 30 minutes, and stored at -20° C until use. No signi¬ 
ficant hemaggluttination activity was found in either the 
immune or normal pools, and no red cell absorptions were 
carried out. 
A sample of rabbit anti mouse (A/Jax strain) lympho¬ 
cyte serum, prepared by the same protocol, was kindly 
donated by Dr. Anthony P. Monaco. 
Cytotoxic Antibody Assay 
a.) Preparation of Cells 
Myeloma cells were harvested from a subcutaneous tumor 
masses in a manner similar to that described above, but 
sterile technique was not rigidly observed, and the tumor 
cells were treated with extra care so as not to damage 
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cells. Tumor masses were cut to small size with two 
Bard-Parker #11. scalpel blades, then teased gently to 
release cells. The suspensions were then either poured 
through a wire mesh, or through a piece of cotton gauze, 
to filter out large particles. The cell suspension was 
allowed to stand for 15 minutes at room temperature to 
allow smaller clumps to settle, whereupon the supernatant 
was poured off and used as a source of viable myeloma cells. 
There was moderate red cell contamination, of course, but 
it was not felt necessary to separate the two cell popu¬ 
lations by centrifugation; indeed, this probably would 
have caused unnecessary damage of tumor cells, 
b.) Cytotoxic Test Procedure 
A simplified test described by Boyse et ah, (3) and 
used by Gray et al, (10), was repeatedly attempted without 
success. This method consists of adding cell suspensions, 
serum dilutions, and complement directly into vaseline 
rings on ordinary slides, incubating at 37°, and reading 
directly the per cent dead (stained) cells. Perhaps our 
source of lyophilized guinea pig complement was inactive. 
At any rate, it was found that the vaseline rings tended 
to melt on the microscope from the heat of the lamp, and 
frequently all the cells clumped against the vaseline ring. 
We rarely saw saw a dead cell, and the "simplified” test 
seemed very unwieldy anyway, so we discarded it, along 
with the reconstituted lyophilized complement. 
Eventually, with the assistance of Dr. Kikuo Nomoto, 
we achieved significant and reproduceable results using a 
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modification of a cytotoxic technique described later by 
Boyse, et.al. (4) All incubations were done in clean, dry 
small test tubes. To each tube was added .25 c.c. of 
doubling dilutions of serum to be tested, whereupon 0,1 c.c. 
containing 10^ cells was immediately added to each tube. 
The mixture was allowed to stand at room temperature for 
15 minutes to allow fixation of antibodies. Then, to each 
tube was added 0,1 c.c. of a 1:5 dilution of freshly prepar¬ 
ed (within 1 week) guinea pig serum as a source of comple¬ 
ment. Tubes were then incubated at 37° for 30 minutes. 
Immediately before reading each tube, 0.1 c.c. of freshly 
prepared 0.2$ trypan blue was added, and the tube was 
then gently shaken, A drop of the cell suspension was 
then placed in a standard white cell counting chamber, and 
the per cent dead cells (blue stained) was determined. All 
tubes that were not going to be read soon, when a lot of 
tubes were to be counted, were put at 4° until about ten 
minutes before reading. Tubes were read in parallel, i,e», 
all the tubes of the same dilution, from each series of 
tubes, were read together, to eliminate bias due to any 
cell death while tubes were waiting to be read. All results 
of cytotoxic antibody determinations have been expressed 
as titration curves of percent dead cells vs, dilution of 
antiserum used. Controls in every experiment included per 
cent dead cells in initial sample (diluted in Hank's only, 
and not incubated), as well as two incubated complement 
controls, read at the beginning and at the end of all read¬ 
ings, respectively. Normal rabbit serum had no activity 
,'tob ei; vt eno st.- • t 
. ■ . , w rfo# .'. • ■> ' 1 lIh 
. 
< . r. ■ ■ 
. 
.l uf • 1 , - ; ■ - ■ . 
. 
. 
, f: v 
■ 
- )*I i ■ 
. ':'v 
....:: - P n 
page 25 
against any cell tested, and it was not felt necessary 
to titrate it every time a cytotoxic assay was done after 
the first couple of times. All dilutions were done in 
Hank's medium with 2% by volume normal rabbit serum, 
Absorptions_ 
a, ) Cell Suspensions 
Sterile cell suspensions were prepared as described 
above, with both lymphocytes and myeloma cells. Packed 
cells were mixed with antiserum, 5$ cells by volume, 
suspended, and left overnight. Cells were gently spun 
down and the procedure was repeated for a total of three 
times, 
b. ) Serum Absorptions 
An experiment was designed to determine the minimum 
quantity of C3H serum needed to absorb out all anti-C3H 
serum protein (or, perhaps, anti-myeloma-produced globulin} 
activity, from the immune serum. To successive tubes 
containing 0.5 c.c, of anti-myeloma serum were added 
aliquots of C3H serum, either straight or diluted represent¬ 
ing 0,3 c.c down to 0,01 c.c. After the tubes had stood 
overnight, a precipitate was visible in all tubes, and 
addition of more C3H serum to the supernate of all tubes 
produced no more precipitate. Accordingly it was judged 
that 2% by volume of C3H serum was adequate to absorb anti¬ 
serum protein activity out of anti-myeloma serum, and this 
was done with a large amount of the serum. 
. " 
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In Vivo Effect on Circulating Lymphocytes 
A series of 8 mice was injected with various sera 
according to the protocol elaborated below, to assay the 
lymphopenic effects of our anti-myeloma serum, normal 
rabbit serum, and Dr. Monacofs anti-lymphocyte serum. All 
blood samples were obtained from animals under light 
Nembutal anesthesia (0.1 c,c/gm of a 7 mg./ml. solution of 
Nembutal, administered i.p.). The anesthetized animals were 
placed under a warm lamp to dilate their tail vessels, and 
a small sample of blood was drawn from a nick in the tail 
into a white cell diluting pipette, and diluted 1:20 with 
0.1# HCL. Total white cell counts were done in a standard 
counting chamber. A drop of blood was placed on a glass 
slide, smeared, and stained with Wrights stain for deter¬ 
mination of per cent lymphocytes. Total lymphocyte counts 
were computed. 
Skin Grafting 
Ventral abdominal and thoracic skin sections, about 
1 cm2, were taken from donor mice and grafted on the 
dorsal thoracic wall of recipients, according to the 
method of Dillingham (2). The selection of the respective 
sites for removal and placement of skin grafts was deter¬ 
mined by the need to obtain skin from an area with fewer 
variations in hair cycles {Dr. Masao Kanaoka - personal 
communication), and to place grafts where the recipients 
could not bite or scratch them off. Plaster casts were 
removed on day 6 (this required anesthesia), and the grafts 
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were followed daily by visual inspection, until destruc¬ 
tion was essentially complete (10# or less of graft surviv¬ 
ing). We have not used the same strains as either Monaco 
and Russell (26, 31)3 or Levey and Medawar (20, 21). 
However, all of these investigators have noted, in the same 
references, that strong histocompatibility differences 
between donor and recipient mice were easily overcome by 
anti-lymphocyte serum. Although we have not raised an 
anti-lymphocyte serum for control, we feel our grafting 
results are comparable to theirs. Our recipient strain 
was chosen because of the availability of a myeloma in 
the same strain (C3H), and our donor strain (Balb/c) was 
chosen for non-scientific reasons (these mice were avail¬ 
able at the time). 
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RESULTS 
Cytotoxic Antibody Studies 
Several attempts at perfecting the technique were 
tried,with unsatisfactory results. Data from these early 
experiments will not be presented. 
Figure 1 shows an experiment done with the perfected 
technique, showing cytotoxic titrations of anti-myeloma 
serum (AMS), anti-lymphocyte serum (ALS), and normal rabbit 
serum (NRS), against myeloma cells. The heavy horizontal 
line represents the percent dead cells in the initial suspen¬ 
sion, Initial and final complement controls were in the 
same range. Clearly, our AMS has a very high cytotoxic 
titer against myeloma cells. Dr, Monaco*s antilymphocyte 
serum has significant activity against the same cells, but 
clearly the AMS has much more effect at higher dilutions. 
Normal rabbit serum has no cytotoxic effects. Points from 
titrations performed with AMS against myeloma cells on two 
other occasions are depicted also. The line is drawn 
through the points attained with the same cell sample used 
for the single ALS titration,however. 
Figure II,depicting an experiment kindly done for us 
by Dr, Kikuo Nomoto, demonstrates that AMS has a signifi¬ 
cant but rather low cytotoxic titer against lymphocytes. 
Figure III represents cytotoxic titration of AMS done 
in parallel with samples of the same serum absorbed with 
lymphocytes (AMS/L), and with myeloma cells (AMS/M). 








FIGURE I - Cytotoxic activity of AMS, AL3, 
and NR3 afainst X5563 myeloma cells 
Horizontal line at 35$ = per cent dead cells in 
initial cell sample 
Initial complement control - 35$ dead cells 
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The three connected lines represent titrations 
done simultaneosly with the same cell sample. 
Separate points from AMS titrations done at 
two other times are drawn, but not connected. 
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FIGURE II - Cytotoxic activity of AMS 
against C3H lymph, node cells 
% dead cells 
l/dil. of antiserum 
Complement control - 21 % 
. 
FIGURE III - Titration of cytotoxic acivity 
of AMS, AMS absorbed with lymphocytes 
(AMS/a), and AMS absorbed with myeloma 
cells (AMS/M) against X5563 myeloma 
cells 
% dead cells 
Horizontal line represents 33^ dead cells in 
initial cell sample 
Initial complement control - 29% dead cells 
Final Complement control - 31$ dead cells 
Legend 
—* AMS 




with myeloma cells should have lowered the curve to the 
baseline of % initial dead cells. It is tempting to con¬ 
clude that, since the AMS/L curve Is not lowered as far as 
the AMS/M curve, there are antigens on the myeloma cell 
foreign to the lymphocyte. This cannot be concluded from 
the experiment, however, until we are able to absorb the 
serum fully with myeloma cells, and perform equivalent 
lymphocyte absorptions. 
It is clear, however, that our AMS has a high titer 
against X5563 myeloma cells, much higher than that of 
Dr. Monaco's very potent ALS, which was prepared identi¬ 
cally. Our AMS also has a very low titer against lympho¬ 
cytes. These data demonstrate that lymphocytes and myeloma 
share some antigenic components. One might argue also that 
they show that each cell type has specific antigens not 
shared by the other. Other factors may be involved in 
determining the cytotoxic titer of a serum versus a cell 
different from that against which It was raised, than the 
degree of antigenic identity of the two cell types one is 
dealing with. We hesitate to conclude with certainty, 
then, that lymphocytes and myeloma cells both have antigens 
not shared by the other, from this experiment alone. To be 
sure, we will have to perform more complete absorptions of 
each serum with both cell types, getting each serum com¬ 
pletely absorbed with its "own" type of cell, absorb equi¬ 
valently with the other cell, and see if any activity remain 






Figure IV shows the results of an experiment performed 
over 120 hours on 8 C3H mice to determine the lymphopenic 
effects of ALS, AMS, and NRS. A total of 4 injections of 
serum was given to each animal. Two animals received 
injections each time of 0.25 c.c. ALS, 0.25 c.c. AMS, and 
0.75 c.c. AMS, One animal got 0.25 c.c. of NRS each time, 
and another got 0.75 c.c. of the same. It is evident that 
all sera had a lymphopenic effect 8 hours after the first 
injection. Clearly, ALS had a far more profound effect 
at this time than the other sera, and this difference was 
maintained throughout the experiment. Animal #6, given 
injections of 0.75 c.c. AMS, had a particularly marked fall 
at 8 hours, but to a level twice as high as that in the 
animal with the lesser response to ALS. After 24 hours 
the lymphocyte count of animal # 6 returned to the range 
of those of NRS recipients, where it stayed. At 46 hours, 
the lymphocyte count of animal # 8, which got 0.25 c.c, 
AMS each time, fell within the range of the counts of ALS 
recipients (which had risen to this level and subsequently 
fell). However, animal # 8’s lymphocyte count was within 
the normal range at all other times. Animals # 5 and 7, 
also recipients of AMS, had lymphocyte counts within the 
normal range at all times. It is quite clear from this 
experiment that Dr. Monaco’s ALS, raised against A/Jax 
lymphocytes, exerted a profound and persistent depression 
over the course of the experiment on the peripheral lympho¬ 
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FIGURE IV - Effect of ALS, AMS, and HRS on 
peripheral lymphocyte counts 
of 03H mice 
1 ympho p y t e s /mm 
Hours 
(serum injections indicated by arrows) 
Legend of serum and doses animal 
given with each injection no. : 
o—o 0.25 c.c. aLS (1,2) 
0.25 c.c. AMS (7,3) 
&—& 0.75 c.c. AMS (5,6) 
A—Jk 0.25 c.c. HRS (3) 
«-« 0.75 c.c. NRS (4) 
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an effect significantly different from that of MRS, even 
though the AMS has a high titer against a cell of C3H 
origin which shares antigens with lymphocytes. 
Skin Grafting 
Several regimens of AMS treatment were tested for 
their effect on the allograft response. Four groups of 
C3H mice received daily i.p. injections, for 7 days, of 
0.25 c.c. AMS, and AMS absorbed with myeloma cells, lympho¬ 
cytes, and C3H serum, respectively. The following day (day 
0) al mice were grafted with Balb/c skin. A control 
group received similar injections of MRS. None of these 
mice received any serum after grafting. Another group 
received injections of 0.25 c.c. AMS for 7 days prior to 
grafting, as well as 0.5 c.c. on days +2 and +6. Still 
another group received daily injections of 0.75 c.c,AMS 
for 5 days prior to graftingj 0.5 c.c. on days 0, +1, +2, 
and +3; and 0.25 c.c. on days +6 and +7. A control group 
received similar injections of NRS. A small number of 
animals had grossly infected grafts when plaster casts were 
removed on day +6, and the recipients of these grafts have 
been excluded from the study. Figure V depicts,day by day, 
the number of surviving grafts observed in each group. The 
day on which a graft was observed to be rejected, and 
removed from the survival table, was chosen as the numerical 
determinant if the number of days the graft survived. The 
mean survival time of grafts in each group has been comput¬ 







. ' ■ , 
, 
-•■'us lo 'rscfnun ©ritf 
page 32 
to calculate standard deviations. Clearly none of the 
serum regimens prolonged allograft survival significantly,. 
In fact, the lower doses of AMS were associated with a 
slightly accelerated rejection, if anything. The sera 
absorbed with cells, we have seen, were not effectively 
absorbed, and can be considered as AMS, Injections in the 
mice that received the very high serum doses were cut back, 
on day +3, because one of the animals in the NRS cage was 
obviously cachectic with weight loss, lethargy, and 
tachypnea. 
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FIGURE V - Effect of various regimens of 
AMS and NRS on the rejection of 
Balb/c shin grafts by C3H mice 
serum 
treatment 
no. of grafts surviving per day 
post grafting 
Day : 
6 7 8 y 10 11 12 13....27 
MST 
(days; 
no serum 11116 4 0 9.0 
o • 2 p c.c* .i.p* 
daily X7 pre- 
graft with: 
NRS 12 12 9 4 2 2 1 0 9.5 
AMS 1212643 1 0 9.1 
' AMS/L. 7 4 4 11 0 8..3 
AMS/M 9 9 3 0 3.3 
AMS/S 6 4 0 7.6 J 
0.25 c.c. daily XJ 
pre-graft, and 0.50 
'c.c. on days +2 and 
+6: AMS 
■ 
4 2 2 0 8.0 
' 0.75 c.c. daily X5 
pre-graft; 0.50 c.c. 
days 0, +1, +2, & +3i 





















AMS/L, AMS/M, AMS/S = AMS absorbed with lymphocytes, 
myeloma cells, and C3H serum, respectively 
M3T - mean survival time of grafts in each series. 
Survival time is defined as the number of the day a graft 
was found to be rejected (i.e. the dajr a graft 
was removed from the survival table). 




We have presented clear evidence that a serum direct¬ 
ed against a cell of C3H origin, other than the lymphocyte, 
has no significant effect on peripheral lymphocyte counts, 
and fails to depress the allograft response, when administer¬ 
ed to C3H mice. In contrast, a serum prepared by the same 
protocol, against the lymphocytes of another strain of 
mice (A/Jax), has a profound lymphopenic effect on C3H mice. 
Our anti-myeloma serum (AMS) has a high cytotoxic antibody 
titer against myeloma cells, and a very low, but signifi¬ 
cant, titer against lymphocytes. In contrast. Dr. Monaco’s 
ALS has a titer against myeloma cells two tubes lower than 
that of AMS. We did not perform a parallel cytotoxic 
titration of ALS against C3H lymphocytes. This titer can 
safely be presumed to be high, however, as Gray et al. (10) 
have shown that the same serum has a leukoagglutionation 
titer against G3H lymphocytes comparable to that achieved 
against A/Jax lymphocytes, which was high. 
Jeejeebhoy (18) has recently objected that cytotoxic 
and leukoagglutinin titers, as well as induction of lympho¬ 
penia, cannot always be correlated with Immunosuppressive 
effects of antilymphocyte sera, and that at present no 
satisfactory test is available for predicting the immuno¬ 
suppressive effects of batches of antilymphocyte serum. 
He raised serum against rat lymphocytes in both dogs and 
rabbits. He maintained that both sera had comparable 
cytotoxic leukoagglutinin activity against rat lymphocytes. 
, 
. O XX-T-' 
. ' 
page 34 
and, seemed to imply that both sera produced initial lympho¬ 
penia in rats, although the rabbit serum did so more effect¬ 
ively; only the rabbit serum had any immunosuppressive 
effects, however. If these observations are accurate, they 
cast considerable doubt on the "cytotoxic" theory, as well 
as upon the validity of much of the in vitro work presented 
above. Jeejeebhoy's cytotoxic titers indeed seem to be 
similarly high with both sera, but close examination of 
his lymphopenia data reveals that, over the course of 4 
hours, his dog anti-rat lymphocyte plasma, which had no 
immunosuppressive effects, had a lymphopenic effect not 
significantly different from that of normal dog plasma. 
He did not follow the lymphocyte counts beyond 4 hours. The 
point that lymphopenia (in the initial stages of serum 
treatment) cannot be correlated with immunosuppressive 
potency is not established by this study. Certainly his 
dog sera did have high in vitro titers against rat lympho¬ 
cytes, however. It is quite conceivable that some dogs 
cannot recognize specific rodent lymphocyte antigens, how¬ 
ever. A non-specific dog anti-lymphocyte preparation 
might then fix just as easily on many other tissues, or be 
eluted easily from lymphocytes onto other tissues. It has 
been shown in the studies of Gray et al. (10), and Monaco 
et al, (26) that the cytotoxic and lymphagglutinatin 
acitivity of their rabbit anti-mouse lymphocyte serum does 
correlate with immunosuppression and lymphopenia. We have 
used this animal system in our experiments, and feel we 
have achieved a good correlation. 
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Further absorption of both sera with both kinds of 
cells, followed by gel-diffusion studies or more cytotoxic 
titrations, are needed to quantitate fully how much anti¬ 
genicity is common to lymphocytes and myeloma cells, as 
well as other tissues (which were not studied here), and 
whether the lymphocyte has specific antigens of its own. 
Nevertheless, our experiments suggest quite clearly, but 
probably in a qualitative way only, that lymphocytes and 
myeloma cells do share some antigens. Other factors may 
be involved, but it is tempting to conclude from our experi¬ 
ments that both the myeloma cell and the lymphocyte are 
capable of raising sera specific for themselves, at least 
having significantly higher titers against the immunizing 
cell than against other cells, and with, in the case of 
ALS, a "clinically" specific in vivo effect. 
It is probably not reasonable to expect the lympho¬ 
cyte to have its entire complement of anitgens cell-speci¬ 
fic, simply because all cells come from the same fertilized 
ovum. Indeed, Russell and Monaco have observed (31) that 
the specificity of ALS may involve the whole array of 
individual specific antigens concerned with histocompati¬ 
bility in allogenic combinations. It is certainly not 
unreasonable to hypothesize that individual cell groups, 
r 
in particular lymphocytes, might have some antigenic 
specificities not present on other cells. The general 
physical availability of lymphocytes, a relative suscepti¬ 
bility to mechanical lysis (or transformation), or a high 
concentration of antigen (either cell or species specific). 
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may be contributing factors in the action of ALS. The 
failure of our high titer anti-myeloma serum, which had 
some activity against lymphocytes, to depress lymphocyte 
counts or prolong graft survival, seems to minimize the 
importance of the latter factors, however, as we might 
have expected AMS to be at least partially effective if 
these mechanisms were critical. It would seem highly 
likely that some degree of cellular antigenic specifi¬ 
city is involved. Levey (20) did achieve immunosuppression 
with an anti-epidermal cell serum, but less than that 
achieved with ALS. His results are not inconsistent with 
our hypothesis. 
ALS had been proven to be a powerful immunosuppressive 
agent. The main practical question involved in the issue 
of specificity, it would seem. Is whether absorption with 
other tissues might be of value in preparation of sera 
for use in vivo. If indeed lymphocytes possess specific 
antigens, one might conceivably expect such absorptions 
to lower the toxicity of the serum, and perhaps to increase 
its effectiveness per given dose - both effects by decreas¬ 
ing avidity for non-lymphoid tissues. 
Our experiments have been directed at the specificity 
of anti-lymphocyte serum and other sera for the lymphocyte. 
We do not offer evidence in favor of either the ''cytotoxic” 
or "sterile activation" theories of the manner of action 
of ALS. Indeed, both theories probably depend on the 
specificity of ALS for the lymphocyte. 
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serum in organ transplantation seem excellent. Hopefully 
our experiments will contribute to the quantitation of 
the degree of immunological specificity this serum has 
for the lymphocytej and to understanding of the relevance 





The current literature pertaining to the specificity 
and mode of action of antilymphocyte serum as an immuno¬ 
suppressive agent has been critically reviewed. Experi¬ 
ments are described in which a serum is raised against 
a mouse (C3H strain) transplantable myeloma. This serum 
has a high cytotoxic antibody titer against myeloma cells, 
and a lower, but significant, titer against C3H lymphocytes. 
In contrast, a potent known antilymphocyte serum, prepared 
by the same protocol, has a relatively lower cytotoxic 
titer against myeloma cells,* this same serum has been 
shown by others to have high agglutination activity against 
C3H lymphocytes. Anti-myeloma serum did not have an 
effect on the lymphocyte counts of C3H mice significantly 
different from that of normal mouse serum, whereas anti¬ 
lymphocyte serum profoundly lowered peripheral lympho¬ 
cyte counts. Finally, antimyeloma serum had no effect on 
the allograft response in any doses, both pre- and post¬ 
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